Nanjing King-friend Biochemical Pharmaceutical Co. Ltd. provided earnings guidance for the first three quarters of 2017. The company predicts that the net profit belonging to shareholders of the listed company in the first three quarters of 2017 will be between RMB 220 million and RMB 230 million, with an increase of between 7.8% and 12.7% compared with the same period of the year before. The net profit excluding extraordinary profit and loss will be between RMB 215 million and RMB 225 million, with an increase of between 147% and 159% compared with the same period of the year before.